[heckel NEWS LETTER] 2021년 9월호

마케팅팀 2022.07.26 조회 34
1) International Congress on Hyperthermic Oncology ICHO 2021 DIGITAL 06.-08. Oktober 2021 - attractive program
For the complete program, click here, for the program booklet here.

Sessions including contributions from heckel whole-body hyperthermia users are:
OP28 - St. van Gool: Effect of whole body hyperthermia on NK cell function in breast cancer patients

Sessions including contributions from the wIRA superficial hyperthermia group are:
06.10.2021 - 16:55-18:15 Session III, Thermo-Biology I
OP08 - A. Thomsen: Improved oxygenation of human skin, subcutis and superficial cancers upon wIRA-hyperthermia – a major sensitizer for subsequent radiotherapy

OP29 - M. Notter: Tissue temperatures and associated sensitising mechanisms upon superficial hyperthermia using water-filtered infrared-A- irradiation – new perspectives

It is such a pity that the congress is just DIGITAL - but let's make a real event by large participation, interesting discussions, and new contacts!

Have also a look at the two ICHO webinars, one of them is presented by heckel, and a full record is available on https://lnkd.in/d6iw7vy

2) New publication: Combined wIRA-hyperthermia and reirradiation for radiation-associated angiosarcoma of the breast

Notter M, Stutz E, Thomsen AR, Vaupel P:
Radiation-Associated Angiosarcoma of the Breast and Chest Wall Treated with Thermography-Controlled, Contactless wIRA-Hyperthermia and Hypofractionated Re-Irradiation Cancers 2021, 13(15), 3911; doi: 10.3390/cancers13153911

Radiation-associated angiosarcoma of the breast (RAASB) is a rare, difficult-to-treat disease. The generally accepted primary therapeutic approach is surgical removal. In contrast, the role of adjuvant and systemic therapies is controversially discussed. The local recurrence rates reported in the literature are most heterogeneous and strongly depend on the extent of surgery. In cases of locally recurrent or irresectable RAASB, the prognosis is poor. 10 patients, most with locally recurrent or inoperable RAASB, were treated with thermography-controlled wIRA hyperthermia combined with re-irradiation. Adjuvant treatment immediately after initial surgery achieved sustained local control, even in case of R2 resection.

Good results were also achieved in local recurrences that developed very quickly after surgery as well as in irresectable tumors. The individual treatment results are described in detail and documented photographically.

3) hydrosun®TWH1500 was put into operation at Guy's and St Thomas' Hospital London / King's College
In August 2021, the Thermography-controlled wIRA-hyperthermia device hydrosun®TWH1500 was installed at Guy's and St Thomas' Hospital London / King's College.

The clinical oncologist responsible for hyperthermia is Anthony Kong MD.
Training was conducted by Andreas Thomsen MD from University Medical Center Freiburg, Dept. of Radiooncology.

It is - as far as we know - currently the only hyperthermia device used in an academic institution in UK. Pictures are available here.

4) New publication of Kleef et al.: Complete remission of a vocal cord cancer by combined treatment protocol of low-dose checkpointinhibitors, Interleukin-2, and hyperthermia
Kleef R, Bacher V, Nagy R, Reisegger P, Bakacs T:
Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and Hyperthermia
Cureus. 2021 Apr 15;13(4):e14500. doi: 10.7759/cureus.14500.

An evaluation of 131 patients treated with this treatment protocol was published in 2020 - Kleef et al. (2020) OPEN ACCES